Combined therapies in osteoporosis: Bisphosphonates and Vitamin D-hormone analogs

Journal of Musculoskeletal Neuronal Interactions

Volumn 7, Issue 2, 2007, Pages 174-184

  Schacht, E ^a   Dukas, L ^b   Richy, Florent ^c  

^a Zurich Osteoporosis Research Group   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bisphosphonates; D hormone analogs; Osteoporosis; Vitamin D

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; MEVALONIC ACID; PARATHYROID HORMONE; PLACEBO; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D DERIVATIVE;

BONE DENSITY; BONE METABOLISM; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FALLING; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; HYPERCALCEMIA; HYPERCALCIURIA; IMMUNE SYSTEM; MEDICAL RESEARCH; METHODOLOGY; MONOTHERAPY; MUSCULOSKELETAL SYSTEM; NERVOUS SYSTEM; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PLEIOTROPY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SECONDARY OSTEOPOROSIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; VERTEBRA FRACTURE; WRIST FRACTURE;

ALENDRONATE; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; HYDROXYCHOLECALCIFEROLS; OSTEOPOROSIS; VITAMIN D;

EID: 34547905038     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Youm T, Koval KJ, Kummer FJ, Zuckerman JD. Do all hip fractures result from a fall? Am J Orthop 1999; 28:190-194.
2. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000.
3. Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC, Genant HK, Hochberg HC, Ensrud KE, Hillier TA, Cauley JA. Risk factors for a first-incident radiographic vertebral fracture in women ≥65 years of age: The study of osteoporotic fractures. J Bone Miner Res 2005; 201:131-140.
4. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344:333-340.
5. Wu-Wong JR, Tian J, Goltzman D. Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Invest Drugs 2004; 5:320-326.
6. Kanis JA. Vitamin D analogs: from renal bone disease to osteoporosis. Kidney Int 1999; 73(Suppl.):S77-S81.
7. Richy F, Ethgen O, Bruyere O, Reginster J-Y. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15:301-310.
8. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus native Vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcif Tissue Int 2005; 76:176-186.
9. Uebelhart D, Frey D, Frey-Rindova P, Goerres G, Michel BA. Therapy of osteoporosis: bisphosphonates, SERMs, teriparatide and strontium. Z Rheumatol 2003; 62:512-517.
10. Boonen S, Body JJ, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY. Evidence-based guidelines for the treatment of post-menopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2005; 16:239-254.
11. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, Lindsay R, Dempster DW. Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res 1998; 13:1721-1729.
12. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990; 5:31-40.
13. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-100.
14. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25:97-106.
15. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct action from estrogen. J Bone Miner Res 2000; 15:770-774.
16. Shibata T, Shiraishi A, Sato T, Masaki T, Masuda A, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito MO, Ito M, Ogata E, Watanabe K, Ikeda K. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 2002; 17:622-629.
17. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100:1475-1480.
18. Boivin GY, Chavassieux PM, Santora, AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27:687-694.
19. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 1999; 65:317-327.
20. DeLuca HF, Cantorna MT. Vitamin D. Its Role and uses in immunology. FASEB J 2001; 15:2579-2585.
21. Inanir A, Ozoran K, Tutkak H, Mermerci B. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in postmenopausal patients with osteoporosis. J Int Med Res 2004; 32:570-582.
22. Scharla SH, Schacht E, Lempert UG. Alfacalcidol versus plain Vitamin D in inflammation induced bone loss. J Rheumatol 2005; 32:26-32.
23. Dambacher MA, David G, Kneer W, Neff M. Praktische Orthopädie - Osteoporose. In: Hedtmann A, Götte S (Hrg). Steinkopff-Verlag, Darmstadt; 2000:49-56.
24. Iwamoto J, Takeda T, Sato Y, Uzawa M. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol 2007; 26:161-167.
25. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005; 90:2762-2767.
26. Ikeda K, Ogata E. The effect of Vitamin D on osteoblasts and osteoclasts. Curr Opin Orthop 1999; 10:339-343.
27. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E. The advantage of alfacalcidol over Vitamin D in the treatment of osteoporosis. Calcif Tissue Int 1999; 65:311-316.
28. 3 are detected only in the presence of a powerful antiresorptive. J Bone Miner Res 2004; 19:S483.
29. 3. J Bone Miner Res 2002; 17:1498-1511.
30. 3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 2002; 89:255-266.
31. Dambacher MA, Schacht E, Scharla SH, Lempert UG. Optimierung der osteoporosetherapie-kombination von alfacalcidol und alendronate. J Miner Stoffwechs 2003; 10:17-20.
32. Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stahelin HB. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52:230-236.
33. Gallagher JC. The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 2004; 89-90:497-501.
34. Dukas L, Schacht E, Mazor Z, Stähelin HB. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 2005; 16:198-203.
35. Schacht E, Richy F, Reginster J-Y. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 2005; 5:273-284.
36. Uusi-Rasi K, Kannus P, Cheng S, Sievanen H, Pasanen M, Heinonen A, Nenonen A, Halleen J, Fuerst T, Genant H, Vuori. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone 2003; 33:132-143.
37. Shiraishi A, Ito M, Hayakawa N, Kubota N, Imai N. Combination therapy with alfacalcidol and risedronate at their subtherapeutic doses can additively improve bone dynamics in ovariectomized rat model of osteoporosis. J Bone Miner Res 2004; 19:S180.
38. Nishikawa T, Ogawa S, Kogita K, Manabe N, Katsumata T, Nakamura K, Kawaguchi H. Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone 2000; 27:647-654.
39. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 1995; 16:603-610.
40. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96:133-138.
41. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000; 11:192-202.
42. Kaptoge S, Benevolenskaya LI, Bhalla AK, Cannata JB, Boonen S, Falch JA, Felsenberg D, Finn JD, Nuti R, Hoszowski K, Lorenc R, Miazgowski T, Jajic I, Lyritis G, Masaryk P. Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone 2005; 36:387-398.
43. Runge M, Schacht E. Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskelet Neuronal Interact 2005; 5:127-134.
44. 3 receptor in human skeletal muscle tissue. Histochem 2001; 33:19-24.
45. Boland R. Role of Vitamin D in skeletal muscle function. Endocr Rev 1986; 784:434-448.
46. Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, Kato S, Matsumoto T. Deletion of Vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003; 144:5138-5144.
47. Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004; 19:265-269.
48. Bischoff HA, Stahelin HB, Urscheler N, Ehrsam R, Vonthein R, Perrig-Chiello P, Tyndall A, Theiler R. Muscle strength in the elderly: its relation to Vitamin D metabolites. Arch Phys Med Rehabil 1999; 80:54-58.
49. Dukas L, Schacht E, Bischoff HA. Better functional mobility in community-dwelling elderly is related to D-hormone serum levels and to a daily calcium intake. J Nutr Health Aging 2005; 9:347-35.1
50. Sorensen OH, Lund B, Saltin B, Lund B, Andersen RB, Hjorth L, Melsen F, Mosekilde L. Myopathy in bone loss of ageing: improvement by treatment with 1-alpha-hydroxycholecalciferol and calcium. Clin Sci 1979; 56:157-161.
51. Verhaar HJJ, Samson MM, Jansen PAF, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and Vitamin D in older women. Aging Clin Exp Res 2000; 12 455-460.
52. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001; 86:3618-3628.
53. Frediani B, Allegri A, Bisogno S, Marcolongo R. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest 1998; 15:235-244.
54. Kataxaki E, Koulouris G, Marketos G, Fragakis N, Georgiadis AE. Combined treatment of alendronate plus alphacalcidol (One-Alpha® LEO Pharma©) on bone mass in postmenopausal osteoporosis. Calcif Tissue Int 2004; 74:S87-S88.
55. Ringe JD, Farahmand P, Schacht E, Rozehnal A. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain Vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 2007; 27:425-439.
56. Ones K, Schacht E, Dukes L, Caglar N. Effects of combined treatment with alendronate and alfacalcidol on bone mineral density and bone turnover in postmenopausal osteoporosis: a two-years randomized, multiarm, controlled trial. The Internet Journal of Epidemiology 2007; Volume 4 Number 1.
57. Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S. Calcitriol and alendronate combination treatment in menopausal women with low bone mass. Int J Tissue React 1999; 21:51-59.
58. Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis 1998; 57:346-349.
59. Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. J Orthop Sci 2003; 8:532-537.
60. Shiota E, Tsuchiya K, Yamaoka K, Kawano O. Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alfacalcidol in postmenopausal osteoporosis. J Orthop Sci 2001; 6:133-136.
61. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333:1437-1443.
62. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE for the Fracture Intervention Trial Research Group: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1535-1541.
63. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G. The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Meta-analysis of the efficacy of Vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23:560-569.
64. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. The Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23:570-578.
65. Greiwe JS, Cheng B, Rubin DC, Yarasheski KE, Semenkovich CF. Resistance exercise decreases skeletal muscle tumor necrosis factor a in frail elderly humans. FASEB J 2001; 15:475-482.
66. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG for the Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339:292-299.
67. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial (Osteoporosis and Bone). Arthritis Rheum 2001; 44:202-211.
68. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, Nielsen K. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9:75-81.
69. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000; 59:48-52.
70. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain Vitamin D in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int 2004; 24:63-70.
71. 3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004; 15:589-602.
72. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004; 350:767-776.
73. 3 1a-hydroxylase promoter. Mol Endocrinol 2004; 18:2440-2450.
74. Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, Stein G. Relationship between disease activity and serum levels of Vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998; 62:193-198.
75. Shane E, Rodino MA, McMahon DJ, Addesso V, Staron RB, Seibel MJ, Mancini D, Michler RE, Lo SH. Prevention of bone loss after heart transplantation with antiresorptive therapy: A pilot study. J Heart Lung Transplant 1998; 17:1089-1096.
76. Godschalk M, Levy RJ, Downs RW. Glucocorticoids decrease Vitamin D receptor numbers and gene expression in human osteosarcoma cells. J Bone Miner Res 1992; 7:21-27.
77. 3 results from ligand-induced stabilization. J Biol Chem 1992; 267:20082-20086.
78. 3 analogs as immunomodulatory agents. Trends Mol Med 2002; 8:174-179.
79. 3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO). Bone Miner 1989; 7:149-158.
80. Briffa NK, Keogh AM, Sambrook PN, Eisman JA. Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation 2003; 75:2133-2134.
81. Frediani B, Allegri A, Storri L, Falsetti P, Bisogno S, Baldi F, Marcolongo R. Alendronate plus calcitriol: a combined treatment in corticosteroid induced osteoporosis. Osteoporos Int 1999; 9:S10-S11.
82. Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001; 16:2111-2117
83. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of Vitamin D on falls. A meta-analysis. JAMA 2004; 291:1999-2006.
84. Miya K, Morimoto S, Fukuo K, Imanaka S, Shiraishi T, Yamamato H, Kitano S, Miyashita Y, Inoue T, Hirotani J. Cognitive function and calcium related factors in elderly female subjects. Nippon Ronen Igakkai Zasshi 1991; 28:34-39.
85. Latham NK, Anderson CS, Lee A, Bennett DA, Moseley A, Cameron ID. A randomized, controlled trial of quadriceps resistance exercise and Vitamin D in frail older people: The frailty interventions trial in elderly subjects (FITNESS). J Am Geriatr Soc 2003; 51:291-299.
86. Smith H, Anderson F, Raphael H, Crozier S, Cooper C. Effect of annual intramuscular Vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial. Osteoporos Int 2004; 15:S8.
87. 3) for prevention of fractures in primary care. BMJ 2005; 330:1003-1006.
88. 3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or Vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365:1621-1628
89. 3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 2003; 32:397-404.